Search
Adrafinil
go.drugbank.com/drugs/DB08925ApprovedWithdrawnIt was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission.
Sipavibart
go.drugbank.com/drugs/DB21908ApprovedInvestigational[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025.
Sibutramine
go.drugbank.com/drugs/DB01105ApprovedIllicitWithdrawnSibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity.
Dextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnDue to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.
Omalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigational[A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005.
Clofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalIt is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand.
Parecoxib
go.drugbank.com/drugs/DB08439ApprovedInvestigationalIt is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. … It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx).
Propanoic acid
go.drugbank.com/drugs/DB03766ApprovedInvestigationalVet approvedWithdrawnIts use as a food additive is also approved in Europe. Sodium propionate is is prepared by neutralizing propionic acid with sodium hydroxide.
Sodium oxybate
go.drugbank.com/drugs/DB09072ApprovedInvestigationalSodium oxybate (Xyrem) is a central nervous system (CNS) depressant used to treat cataplexy or excessive daytime sleepiness associated with narcolepsy. It is a sodium salt of gamma-Hydroxybutyric acid, an endogenous cerebral inhibitory n...
Cerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigationalCerliponase alfa is a hydrolytic lysosomal N-terminal tripeptidyl peptidase-1 (TPP1). On April 27, 2017, cerliponase alfa was first approved by the FDA as the first treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), also known a...